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Immune-mediated motor polyneuropathies including Guillain-Barre´syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are rare but serious complications of HSCT, because they are characterized by potentially life-threatening motor deficits. 1 Although both GBS and CIDP share many features, including flaccid paralysis, elevated CSF protein levels and electromyographic findings, they are considered separate clinical entities. 2 Clinically, CIDP is distinguished from GBS by its course, which consists of a gradual progression over more than 2 months. 2 Since the relevant literature has been almost exclusively limited to case reports, the clinical characteristics of GBS and CIDP after HSCT have yet to be elucidated.
A 58-year-old Japanese woman in the first remission of acute lymphoblastic leukemia underwent allogeneic bone marrow transplantation from a human leukocyte antigenidentical sibling. The conditioning regimen comprised cyclophosphamide, cytosine arabinoside and total body irradiation. Cyclosporine A and short-term methotrexate were used as prophylaxis against graft-versus-host disease (GVHD). As indicated in Figure 1 , diffuse erythema and diarrhea developed on day 42 and a skin biopsy revealed acute GVHD. Prednisolone (PSL 1 mg/kg) administration was started to treat the GVHD. On day 140 during the tapering of PSL, the patient developed chronic GVHD involving the skin and mouth. On day 162, she complained of numbness in the distal extremities. On day 175, she developed muscle weakness in the lower extremities, which progressed to severe quadriplegia by day 180. Muscle strength on the Medical Research Council scale was grade 2 in the arms and grade 1 in the thighs. The patient complained of numbness in the fingers and feet, but objective sensation was preserved. All deep tendon reflexes were absent. Autonomic nervous system function, cranial nerve function and respiratory function were normal. Magnetic resonance images of the whole spinal cord showed no abnormalities. CSF protein was 64 mg/dl with 4 cells/ml. The patient's serum was negative for antiganglioside antibodies. Nerve conduction studies showed delayed motor nerve conduction (42 m/s in the median nerve and 33 m/s in the tibial nerve) with dymyelinating features. Intravenous immunoglobulin therapy (IVIg) at a dose of 400 mg/kg/day was performed for 5 days starting from day 180, but no improvement was observed. Steroid pulse therapy (methyl-PSL, 1000 mg/day for 3 days) followed by high-dose PSL was given. The patient began to gradually recover from the weakness on day 240, and muscle strength in her arms improved to grade 4. However, her lower extremity function did not respond to therapy and she remained bedridden. The patient again developed systemic diffuse erythema on day 327. The chronic GVHD was progressive, while her muscle weakness was unchanged. Immunosuppressive therapy with PSL and tacrolimus was started on day 390, and she developed a series of systemic infections, and died of Stenotrophomonas maltophilia septicemia on day 445.
The present patient showed characteristic features of GBS in the acute phase with rapid progression of symptoms over several days. She partially recovered within 2-4 months of initial treatment, although the degree of recovery was not sufficient. Repeated electromyographic findings also showed demyelinating changes. Since a sural nerve biopsy was not performed, the final diagnosis was 'probable CIDP'. It has been reported that 2% of GBS patients are later diagnosed as having CIDP.
3 GBS and CIDP differ not only in the duration of progression and prognosis but also in the response to treatment. Patients with CIDP often require further steroid or other immunosuppressive treatment in addition to IVIg or plasma exchange. To disclose clinical features that differ between GBS and CIDP occurring after HSCT, we used PubMed (www.ncbi.nlm.nih.gov) to search the literature for cases of GBS and CIDP that had developed after HSCT to treat hematological disorders. The diagnoses of GBS and CIDP were carefully evaluated based on specific diagnostic criteria. 2 Patients with GBS who experienced a recurrence of weakness after 4 weeks of treatment were regarded as having CIDP. We excluded case reports showing only sensory symptoms and diagnosed as having peripheral neuropathy at the time of HSCT.
As a result, we were able to evaluate 19 cases of GBS and 9 cases of CIDP, including our own case. 1, [4] [5] [6] [7] [8] [9] [10] The clinical characteristics of the patients with GBS and CIDP are shown in Table 1 . There were no differences between the two groups in demographic features, including primary diseases and conditionings or transplant procedures. More male patients were affected than females. With respect to the primary disease, CML was most frequent. Most of the cases were recipients of allogeneic HSCT. On the other hand, the frequencies of antecedent infection, GVHD at onset and mechanical ventilation were different between the GBS and CIDP groups.
GBS results from immune responses to non-self antigens (infectious antigens) that misdirect to host nerve tissue through a molecular mimicry mechanism. 2 In the present series, GBS tended to develop the following infection in the early phase within 3 months after HSCT. The most frequent pathogen was cytomegalovirus.
Particularly in GBS patients, the incidence of both respiratory failure and mortality due to GBS or infection was high.
By contrast, CIDP developed in the late phase after HSCT and was often associated with chronic GVHD. CIDP may be associated with concurrent diseases, such as infection with human immunodeficiency virus or hepatitis C, inflammatory disease, diabetes mellitus, monoclonal gammopathy and lymphoma. 2 Chronic GVHD is associated with loss of self-tolerance, and its clinical manifestations often resemble those of autoimmune diseases. These findings suggest that chronic GVHD causes immune dysregulation, and thus predisposes patients to develop CIDP after HSCT.
In conclusion, neurologists and transplant physicians should be aware of the differences between the clinical features of GBS and CIDP that develop after HSCT. 
